Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12276143 | 0.90 | POLB (0.53) | POLBALOX15MAPTTP53LMNA | |
| SCHEMBL2409605 | 0.83 | MEN1 (0.57) | POLBMAPTTP53LMNAHTT | |
| SCHEMBL2412445 | 0.83 | SMN1; SMN2 (0.48) | POLBMAPTTP53LMNAHTT | |
| SCHEMBL2413442 | 0.80 | CTPS1 (0.48) | MAPTTP53LMNAHTTALDH1A1 | |
| SCHEMBL2413792 | 0.80 | CTPS1 (0.48) | POLBMAPTTP53LMNAHTT | |
| SCHEMBL2416071 | 0.78 | LMNA (0.60) | MAPTTP53LMNAHTTSMN1; SMN2 | |
| SCHEMBL5561572 | 0.76 | MAPT (0.54) | POLBMAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12274759 | 0.75 | MEN1 (0.52) | POLBALOX15MAPTTP53LMNA | |
| SCHEMBL12275540 | 0.73 | SMN1; SMN2 (0.46) | POLBMAPTTP53LMNAHTT | |
| SCHEMBL2408480 | 0.73 | MAPT (0.43) | POLBMAPTTP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | POLB 3392/4885ALOX15 708/4885MAPT 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.